Business Wire

WarnerMedia to Take Full Ownership of HBO-Branded Services in Spanish-Speaking Latin America and the Caribbean, Including All HBO, MAX, Cinemax and HBO Go Offerings

Share

WarnerMedia has reached an agreement to buy Ole Communications’ minority stake in HBO Ole Partners, the joint venture between WarnerMedia and Ole Communications. When the transaction closes, WarnerMedia will own 100% of all HBO, MAX, Cinemax and HBO Go services in Spanish-speaking Latin America and the Caribbean. The ownership structure of HBO Brasil Partners, another joint venture between the companies that operates HBO in Brazil, is unaffected at this time. WarnerMedia and Ole Communications will continue their basic channel distribution business in Latin America.

The transaction is expected to be completed following the granting of relevant regulatory approvals. Upon completion, HBO Ole Partners will fall under the purview of Gerhard Zeiler, Chief Revenue Officer, WarnerMedia & President, WarnerMedia International Networks.

“We’re excited to own all of HBO Ole Partners, which operates one of the leading premium, subscription-based television networks in the region. The acquisition will allow us to bring localized versions of our upcoming U.S. streaming service HBO Max to consumers in Spanish speaking Latin America and the Caribbean,” said Zeiler. “We have the option to acquire the business in Brazil but are not doing so at this time. As we have said, additional, direct investment in Brazil is not currently attractive to us because of the existing regulatory uncertainty in the country. We support and remain optimistic about the ongoing efforts to amend the SeAC law to ensure the media industry has a clear and predictable regulatory framework that fosters investment and innovation.”

“WarnerMedia has been a great partner in Latin America and we are proud to have built the HBO-branded networks in the region together,” said Enrique Cusco, President and CEO of Ole Communications. “We are pleased that we will continue the business of distributing our great portfolio of basic channels in the market, a portfolio that includes Warner Channel and the channels of A+E Networks Latin America, NBCUniversal International Networks Spanish Latin America and Sony Pictures Entertainment.”

WarnerMedia and Ole Communications brought HBO programming services to the region for the first time when they founded the HBO Ole Partners joint venture in 1991 and launched a Spanish-language HBO-branded premium channel that same year. In 1994, a Portuguese-language service was launched in Brazil.

About HBO Max

HBO Max is a new streaming service which will offer an impressive direct-to-consumer experience for everyone, ranging from families with young children to adults of all ages. Anchored with and inspired by the legacy of HBO’s excellence and award-winning storytelling, the new service will feature an extensive collection of exclusive original programming (Max Originals) and the best-of-the-best from WarnerMedia’s enormous portfolio of beloved brands and libraries.

About WarnerMedia

WarnerMedia is a leading media and entertainment company that creates and distributes premium and popular content from a diverse array of talented storytellers and journalists to global audiences through its consumer brands including: HBO, HBO Now, HBO Max, Warner Bros., TNT, TBS, truTV, CNN, DC Entertainment, New Line, Cartoon Network, Adult Swim, Turner Classic Movies and others. WarnerMedia is part of AT&T Inc. (NYSE:T).

About Ole Communications

Ole Communications is an international multi-media company and a pioneer in the Latin American pay television industry. The Company’s various joint ventures include A+E Networks Latin America, NBCUniversal International Networks Spanish Latin America, HBO Brasil Partners, IVC Networks and PlayGround Americas. Through its affiliates, the Company distributes the leading pay television brands in Latin America, such as A&E, AXN, History, H2, IVC, Lifetime, E! Entertainment, Studio Universal, Sony Channel, SyFy, Telemundo Internacional, Universal TV and Warner Channel. To support its joint ventures and strategic partners throughout Latin America, Ole Communications, through its VC Medios affiliates, provides advertising sales representation services as well as broadcast, languaging, and production services.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Oliver Herrgesell, EVP Communications, WarnerMedia Sales & International
oliver.herrgesell@turner.com +1 212 275 6794

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 20268.12.2025 09:00:00 EET | Press release

Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “By presenting these new data at TOXINS 2026, we aim to foster scientific exchange and advance treatment strategies that address real-world challenges for patients and clinicians.” Merz Therapeutics will share new findings reflecting its continued dedication to advancing neurotoxin science. These include: Lower Limb Spasticity Incobotulinumto

Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 08:05:00 EET | Press release

Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additionally, Galderma and L’Oréal aim at exploring additional scientific research projects of mutual interest. This ongoing collaboration brings together Galderma’s scientific leadership i

Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release

Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye